Journal of Neurology

, Volume 258, Issue 4, pp 686–688 | Cite as

Disease-relevant autoantibodies in first episode schizophrenia

  • Michael S. Zandi
  • Sarosh R. Irani
  • Bethan Lang
  • Patrick Waters
  • Peter B. Jones
  • Peter McKenna
  • Alasdair J. Coles
  • Angela Vincent
  • Belinda R. LennoxEmail author
Open Access
Letter to the Editors


Schizophrenia Psychotic Disorder Limbic Encephalitis Delusional Disorder Episode Psychosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Dear Sirs,

Schizophrenia is a common, heterogenous and complex disorder with unknown aetiology [1]. There is established evidence for N-methyl-d-aspartate receptor (NMDAR) hypofunction [2] as a central component of the functional dysconnectivity that is the most accepted model for symptoms [3], and increasing evidence for potassium channel dysfunction [4]. Moreover, autoimmune mechanisms have been proposed, perhaps in subgroups of patients [5, 6]. In the last few years, antibodies to neuronal cell surface antigens have been identified in cases of autoimmune encephalitis that respond to immunotherapy [7, 8]. Over two-thirds of patients with NMDAR antibody encephalitis, and some with potassium channel antibody-associated limbic encephalitis, have prominent psychiatric symptoms, or may present to psychiatric services in the first instance [7, 9, 10]. The psychiatric symptoms are those seen in schizophrenia including delusions, hallucinations, and catatonic movement disorder. There is good evidence for specificity and pathogenicity of these antibodies, with absence in large numbers of healthy individuals and those with other neurological diseases [9, 11, 12]. However, there have been no cases of NMDAR or potassium channel antibodies identified in patients with purely psychiatric disorders. We hypothesized that these antibodies would be present in a proportion of patients with early schizophrenia, in the absence of overt seizures, movement disorders, or other neurological signs.

Serum was obtained prospectively from a cohort (n = 46) of patients at first presentation of psychosis to an epidemiologically principled early intervention for psychosis service (, which provides 3 years of treatment and follow up when possible. We retrospectively measured NMDAR antibodies using a cell based assay and subjective visual scoring system [9]. We identified antibodies to components of potassium channel complexes (VGKCs) by radioimmunoassay [8]. The sera were tested blind to diagnostic status. Patients with positive results were retrospectively interviewed and extensively investigated. Full clinical details are given in the Table and supplementary information.

Patients 1 and 2 had NMDAR antibodies, [patient 1: score 2, (range 0–4, normal 0–0.5, Fig. 1); patient 2: score 1]. Patient 1 was unwell for 6 months before recovering; he was well and antibody negative at 3 years. Patient 2 has had a protracted course; antibodies remained repeatedly positive at 24–35 months follow up, but were then negative at 36 months. Patient 3 had VGKC antibodies (1,435 pM; normal <100), was unwell for 6 months before recovering, but has subsequently relapsed after 1 year and has now been lost to follow up. There were no clinical features to differentiate these cases from other cases of psychosis in Cameo (Table 1), even in retrospect, and the autoantibody positive cases fulfilled criteria for DSM-IV schizophrenia. No patient had physical neurological symptoms or signs.
Fig. 1

HEK cells co-transfected with NR1, NR2B and EGFP cDNA or transfected with EGFP cDNA alone. Serum of patient 1 bound to the surface of unpermeabilised cells transfected with NMDARs, but not EGFP alone. Healthy controls (Control) showed no binding

Table 1

Demographic and clinical data for antibody positive cases


Antibody, titre



Illness duration at intake/assay (days)

Positive psychotic symptoms

Negative psychotic symptoms

Cognitive deficits

Time to recovery, time to relapse, (months)

Total follow up (months)


NMDAR score 2




Grandiose and paranoid delusions, delusions of control

Anergia, poor motivation

Verbal fluency

6, n/a



NMDAR score 1




Auditory verbal hallucinations. Paranoid delusions, delusions of control






VGKC 1435 pM




Paranoid delusions, thought disorder

Poor self care and motivation, anergia

Working memory

6, 12



NMDAR score 1.5




Auditory verbal hallucinations, thought disorder, paranoid grandiose delusions

Poor motivation, social withdrawal, incongruent affect

Recall and verbal fluency

5 (partial), n/a


Antibody negative Cameo cases n = 43


M:F 4:1

22 (17–35)

145 (2–270)

Auditory hallucinations, paranoid grandiose delusions

Social withdrawal

Not known

Chronic 23%


Relapse 58%

No relapse 19%

A further patient, patient 4, with first episode psychosis identified after the prospective cohort, had NMDAR antibodies (score 1.5). He was unwell for 4 months, partially responsive and then relapsing despite treatment with antipsychotics. To reduce the levels of NMDAR antibodies he received plasmapheresis and made a significant clinical improvement 3 weeks later, improving further with prednisolone. He remains clinically and functionally improved at 7 month follow up, on no antipsychotic medication. This is the first case description, to our knowledge, of a patient with NMDAR antibodies and a purely psychiatric presentation responding to immunotherapy.

These preliminary data show that some patients with schizophrenia have potentially pathogenic autoantibodies to relevant membrane proteins. Three of the patients had NMDAR antibodies, which have been shown to reduce NMDAR clusters in vivo [12], which mirrors that seen in models of schizophrenia [13]. All of our antibody positive cases (6.5% of 46) fulfilled DSMIV criteria for schizophrenia and the patients were tested early in the course of their illness. None of the chronic schizophrenia controls in our large case series had NMDAR antibodies [9], but this could be because NMDAR and VGKC antibodies spontaneously drop with time ([14]; SRI, AV unpublished data); this suggests a critical early period of illness for detection and treatment. We did not measure antibody in CSF, and future prospective systematic studies of antibody in paired serum and CSF will be informative.

The 46 patients in the Cameo cohort were given DSM-IV diagnoses a year after intake to the service. Of these, 63% had a diagnosis of schizophrenia. Other psychotic diagnoses were psychosis not otherwise specified (15%), bipolar affective disorder (13%), schizoaffective disorder (4%), major depression with psychosis (2%) and delusional disorder (2%). It is therefore possible that the proportion of cases with diagnoses of schizophrenia that have specific antibodies is higher than the proportion described here. However, there is significant diagnostic instability in patients with early psychosis, due to the threshold of chronicity required for a diagnosis of schizophrenia. There is also increasing evidence of shared heritability between the psychotic disorders and consequently a move away from the use of categorical diagnoses in those with psychotic disorders.

There is a need for a systematic screen of available neuronal surface antigens in first episode psychosis and schizophrenia to characterise the true prevalence of these antibodies among different population groups, with implications for diagnosis, prognosis and treatment.



This work was supported by the National Institute for Health Research (NIHR) CLAHRC for Cambridgeshire and Peterborough, CIBERSAM, Spain and the Oxford Biomedical Research Centre. MSZ holds an Eastern Region Neurosciences Training Fellowship. SRI held an NIHR clinical training fellowship. We also wish to acknowledge Professor F. Anne Stephenson, at the School of Pharmacy, University of London for her help in developing the NMDAR assay. We would like to thank Prof D Beeson and Ms S Maxwell for their assistance with the cloning and expression of NMDAR subunits, Dr F Winton as clinical referrer and Dr J Stochl for help with the Cameo demographic data.

Conflict of interest

MZ and PW report no disclosures. SRI, PBJ and BLe receive support from the NIHR. AJC reports receiving consulting fees, lecture fees, and grant support from Genzyme. PMcK is supported by CIBERSAM, Spain. AV receives royalties from Athena Diagnostics, and the department of Clinical Neurology in Oxford receives royalties and payments for antibody assays.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Supplementary material

415_2010_5788_MOESM1_ESM.doc (41 kb)
Supplementary material 1 (DOC 41 kb)


  1. 1.
    Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40–68Google Scholar
  2. 2.
    Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108PubMedCrossRefGoogle Scholar
  3. 3.
    Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35:509–527PubMedCrossRefGoogle Scholar
  4. 4.
    Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V et al (2009) A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 15:509–518PubMedCrossRefGoogle Scholar
  5. 5.
    Jones AL, Mowry BJ, Pender MP, Greer JM (2005) Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 83:9–17PubMedCrossRefGoogle Scholar
  6. 6.
    Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al (2009) Common variants conferring risk of schizophrenia. Nature 460:744–747PubMedGoogle Scholar
  7. 7.
    Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098PubMedCrossRefGoogle Scholar
  8. 8.
    Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N et al (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127:701–712PubMedCrossRefGoogle Scholar
  9. 9.
    Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS et al (2010) N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667PubMedCrossRefGoogle Scholar
  10. 10.
    Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ et al (2006) Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report. Br J Psychiatry 189:182–183PubMedCrossRefGoogle Scholar
  11. 11.
    Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A et al (2007) Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36PubMedCrossRefGoogle Scholar
  12. 12.
    Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R et al (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30:5866–5875PubMedCrossRefGoogle Scholar
  13. 13.
    Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13:76–83PubMedCrossRefGoogle Scholar
  14. 14.
    Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M et al (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50:73–78Google Scholar

Copyright information

© The Author(s) 2010

Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Michael S. Zandi
    • 1
  • Sarosh R. Irani
    • 2
  • Bethan Lang
    • 2
  • Patrick Waters
    • 2
  • Peter B. Jones
    • 3
  • Peter McKenna
    • 4
  • Alasdair J. Coles
    • 1
  • Angela Vincent
    • 2
  • Belinda R. Lennox
    • 3
    Email author
  1. 1.Neurology Unit, Department of Clinical NeurosciencesUniversity of Cambridge, Addenbrooke’s HospitalCambridgeUK
  2. 2.Neurosciences Group, Department of Clinical NeurologyUniversity of Oxford, John Radcliffe HospitalOxfordUK
  3. 3.Department of PsychiatryUniversity of CambridgeCambridgeUK
  4. 4.Benito Menni Complex Assistencial en Salut Mental, CIBERSAMBarcelonaSpain

Personalised recommendations